Global Short Bowel Syndrome Market Size By Type (GLP-2, Growth Hormone), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

lobal Short Bowel Syndrome Market Report Description

The Global Short Bowel Syndrome Market was valued at USD 752 million in 2023 and is expected to reach USD 1.42 billion by 2031, expanding at a CAGR of 8.1% during the forecast period from 2023 to 2031. This growth is fueled by increased prevalence of gastrointestinal disorders, rising awareness about rare diseases, and advances in parenteral nutrition and therapeutic treatments. Short bowel syndrome (SBS), a complex condition often arising from surgical resection of the small intestine, demands long-term nutritional and medical management, which is driving innovation and investment in novel treatment solutions.

Drivers:

1. Rising Prevalence of Gastrointestinal Disorders:

The increasing incidence of conditions such as Crohn's disease and intestinal cancer, which often necessitate bowel resections, is a major contributor to the growing patient pool affected by SBS.

2. Advances in Parenteral Nutrition and GLP-2 Analogues:

Innovations in nutritional support and medications like teduglutide are significantly improving the quality of life for patients with SBS, enhancing nutrient absorption and reducing dependence on intravenous feeding.

3. Increased Awareness and Orphan Drug Designation:

Global health campaigns and the orphan drug status granted to SBS treatments in many regions are encouraging pharmaceutical companies to invest in research and development.

Restraints:

1. High Treatment Costs:

The financial burden associated with long-term parenteral nutrition and specialty drugs continues to be a major barrier, especially in low- and middle-income countries.

2. Limited Access in Emerging Economies:

Insufficient healthcare infrastructure and lack of specialized care facilities in developing regions limit early diagnosis and effective management of SBS.

Opportunity:

1. Expansion of Home Parenteral Nutrition (HPN):

Advancements in HPN technologies and growing patient preference for home-based care are opening new avenues for market growth, reducing hospital dependency and improving patient outcomes.

2. Biotech and Pharmaceutical Innovation:

The ongoing development of regenerative medicine and bioengineered intestines presents future opportunities for curative solutions beyond current treatment limitations.

Market by System Type Insights:

By treatment type, the pharmacologic therapy segment, especially GLP-2 analogs like teduglutide, accounted for the largest market share in 2023. These therapies promote intestinal growth and absorption, reducing the need for parenteral support. The nutritional support segment, including both enteral and parenteral nutrition, also plays a crucial role and is expected to see consistent demand due to the chronic nature of the condition.

Market by End-Use Insights:

Hospitals remained the largest end-use segment in 2023, attributed to the need for specialized diagnosis and initial treatment initiation. However, the home care segment is expected to experience the highest growth during the forecast period as patients and providers shift towards long-term management in home settings with the aid of portable HPN systems.

Market by Regional Insights:

North America led the market in 2023, driven by high disease awareness, advanced healthcare infrastructure, and active clinical research. Europe follows closely, while the Asia-Pacific region is poised for the fastest growth owing to improving healthcare access, growing patient populations, and increased government initiatives focused on rare diseases.

Competitive Scenario:

Key players in the global Short Bowel Syndrome market include:

Takeda Pharmaceutical Company Limited

Zealand Pharma A/S

Napo Pharmaceuticals

Nutricia (Danone)

Pfizer Inc.

AbbVie Inc.

Teva Pharmaceutical Industries Ltd.

Baxter International Inc.

These companies are emphasizing innovation, expanding access to therapies, and engaging in partnerships with research institutes and hospitals to develop next-generation treatments.

Scope of Work – Global Short Bowel Syndrome Market

Key Market Developments:

2023: Takeda launched updated clinical trial data for teduglutide, reinforcing its effectiveness in reducing dependence on parenteral nutrition.

2024: Zealand Pharma received regulatory clearance in the EU for glepaglutide, a next-gen GLP-2 analog, expanding its reach in the SBS market.

2025: Napo Pharmaceuticals announced a pipeline product focused on pediatric SBS, highlighting the growing emphasis on unmet needs in younger populations.

FAQs:

What is the current market size of the Global Short Bowel Syndrome Market?

The market was valued at USD 752 million in 2023.

What is the major growth driver of the Global Short Bowel Syndrome Market?

Rising prevalence of gastrointestinal disorders and innovative pharmacologic therapies are major drivers.

Which is the largest region during the forecast period in the Global Short Bowel Syndrome Market?

North America is expected to maintain its dominance.

Which segment accounted for the largest market share in the Global Short Bowel Syndrome Market?

The pharmacologic therapy segment accounted for the largest share in 2023.

Who are the key market players in the Global Short Bowel Syndrome Market?

Key players include Takeda, Zealand Pharma, Napo Pharmaceuticals, Nutricia, and Pfizer.

Let me know if you'd like this formatted into a document or if you'd like assistance with another topic.